2. Have a histologically proven BCC in which curative resection is unlikely without significant morbidity, or have nodal or distantly metastatic disease which has progressed on smoothened inhibitor monotherapy (ARM 1) or has undergone partial response or stable disease on smoothened inhibitor monotherapy (ARM 2). Individuals who are intolerant or have a medical contra-indication to smoothened inhibitor will be enrolled into ARM 1, but will not be included in the formal analysis.